Opioid use among patients with inflammatory bowel disease: a systematic review and meta-analysis
B Niccum, O Moninuola, K Miller, H Khalili - Clinical Gastroenterology and …, 2021 - Elsevier
Background and Aims Despite reported adverse effects of opioids in patients with
inflammatory bowel disease (IBD), the burden of opioid use in this population appears to be …
inflammatory bowel disease (IBD), the burden of opioid use in this population appears to be …
Tofacitinib treatment safety in moderate to severe ulcerative colitis: comparison of observational population cohort data from the IBM MarketScan® administrative …
JR Curtis, M Regueiro, H Yun, C Su… - Inflammatory Bowel …, 2021 - academic.oup.com
Background Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of
ulcerative colitis (UC). We aimed to estimate the overall incidence of safety events in …
ulcerative colitis (UC). We aimed to estimate the overall incidence of safety events in …
Real-world persistence, maintenance dosing, and pre-post corticosteroid and opioid use among Crohn's disease patients with prescription claims for ustekinumab in …
Z Ding, C Obando, E Muser, C Kozma… - Drugs-Real World …, 2021 - Springer
Background Real-world evidence for how US Crohn's disease (CD) patients use
ustekinumab is limited. Objectives The aim of this study was to describe the persistence …
ustekinumab is limited. Objectives The aim of this study was to describe the persistence …
A 20-year evaluation of LOINC in the United States' largest integrated health system
A Bhargava, T Kim, DB Quine… - Archives of pathology …, 2020 - meridian.allenpress.com
Context.—Clinical laboratories are obligated to implement Logical Observation Identifier
Names and Codes (LOINC), an informatics standard used to uniquely identify laboratory …
Names and Codes (LOINC), an informatics standard used to uniquely identify laboratory …
Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: a claims database analysis
T Kobayashi, E Udagawa, A Uda, T Hibi… - Journal of …, 2020 - Wiley Online Library
Abstract Background and Aim It is unclear how adding an anti‐tumor necrosis factor alpha
agent to immunomodulator (IM) treatment, as a step‐up strategy, affects long‐term outcomes …
agent to immunomodulator (IM) treatment, as a step‐up strategy, affects long‐term outcomes …
Worse outcomes and higher costs of care in fibrostenotic Crohn's disease: a real-world propensity-matched analysis in the USA
M Dehghan, G Wong, E Neuberger… - BMJ Open …, 2021 - bmjopengastro.bmj.com
Background Patients with Crohn's disease (CD) may develop fibrostenotic strictures. No
currently available therapies prevent or treat fibrostenotic CD (FCD), making this a critical …
currently available therapies prevent or treat fibrostenotic CD (FCD), making this a critical …